Entocord 0,02 Mg/Ml (Enema) 0,02 mg/ml Dispersible tablet and solution for rectal suspension
PDF Leaflet Revision Date: 24 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Ulcerative colitis involving the rectum and sigmoid colon.
Dosage (summary)
One enema nightly for 4 weeks; may extend to 8 weeks if no remission.
Onset of Action / Duration
Onset: 2-4 weeks, Duration: Not specified.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and breastfeeding not established; corticosteroids are teratogenic.
Key Drug Interactions
- CYP3A inhibitors (e.g., ketoconazole)
- CYP3A4 inducers (e.g., carbamazepine)
Contraindications
- Hypersensitivity to budesonide
- Bacterial, fungal, or viral infections
- Children
Common side effects
- Nausea
- Diarrhoea
- Depression
- Urticaria
Counselling Points
- Administer enema at bedtime
- Monitor for systemic side effects
- Report any allergic reactions
Serious warnings
- Adrenocortical suppression risk
- Systemic corticosteroid effects
- Visual disturbances
Important Disclaimer
The Entocord 0,02 Mg/Ml (Enema) 0,02 mg/ml Dispersible tablet and solution for rectal suspension professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
